Research
Commonly mutated gene could be a therapeutic target in sarcoma
The Brief
- Researchers at MD Anderson Cancer Center report that sarcomas lacking the ATRX gene tend to be more aggressive.
- Such sarcomas may be particularly vulnerable to TEAD inhibitors, a class of targeted therapies.
Why it matters
ATRX loss may help identify sarcoma patients who could respond to TEAD inhibitors, pointing to a possible targeted treatment approach for a commonly mutated gene.
Who’s affected
- oncologists and sarcoma researchers
- patients with ATRX-deficient sarcomas
- #sarcoma
- #atrx
- #cancer
- #targeted therapy
- #tead inhibitors
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a…